Drugs / ANT3310
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06916156 | Apr → Aug 2025 | — | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT06527677 | Jul 2024 → Jul 2025 | impaired renal function disease | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT05905913 | Apr 2023 → Jan 2024 | — | Antabio | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANT3310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905913 ↗ |
| Action | Inhibit | “ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases” NCT05905913 ↗ |
| Route | Intravenous | “ANT3310 will be infused over 3 hours” NCT05905913 ↗ |